SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (2711)12/14/2011 8:22:46 PM
From: software salesperson  Read Replies (2) | Respond to of 3202
 
from today's oppenheimer healthcare conference re: 050 :

tofacitinib is cleared thru enzymes in the liver. since 050 is cleared thru the kidney, we expect less drug interactions.

can anyone shed any light on this comparison?

thanks.